Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Inclusion Criteria:

* Written, signed, IRB-approved informed consent form.
* Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced solid tumor.
* Patients must have a pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
* One or more tumors measurable by RECIST criteria.
* Karnofsky performance status ≥ 70%.
* Ejection fraction ≥ 50%, determined by echocardiogram.
* Life expectancy at least 3 months.
* Age ≥ 18 years.
* Acceptable organ function; normal hepatic, renal and hematopoietic function.
* Negative serum or urine pregnancy test result in women of childbearing potential.

Exclusion Criteria:

* Known brain metastasis.
* New York Heart Association Class III or IV cardiac disease, myocardial infarction within 6 months of enrollment, or cardiac arrhythmia requiring medical therapy.
* Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
* Patients with uncontrolled diabetes (requiring medication change within 30 days of screening), or requiring insulin therapy.
* Heparin therapy.
* Known infection with HIV, hepatitis B, or hepatitis C.
* Known allergy to hyaluronidase.
* Women currently breast feeding.